Factor Xa-inhibition in interventional cardiology
Ahrens I, Peter K, Bode C.
Hamostaseologie. 2007 Dec;27(5):328-32.
http://www.ncbi.nlm.nih.gov/pubmed/18060241

Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.
Ahrens I, Smith BK, Bode C, Peter K.
Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):609-20.
http://www.ncbi.nlm.nih.gov/pubmed/17696810

CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1.
Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, Ahrens I, Ernst S, Bassler N, Missiou A, Patko Z, Aikawa M, Schönbeck U, Bode C, Libby P, Peter K.
Circulation, 2007 Mar 27;115(12):1571-80
http://www.ncbi.nlm.nih.gov/pubmed/17372166

Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
Stoll P, Bassler N, Hagemeyer CE, Eisenhardt SU, Chen YC, Schmidt R, Schwarz M, Ahrens I, Katagiri Y, Pannen B, Bode C, Peter K.
Arterioscler Thromb Vasc Biol. 2007 May;27(5):1206-12
http://www.ncbi.nlm.nih.gov/pubmed/17322097

A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists.
Bassler N, Loeffler C, Mangin P, Yuan Y, Schwarz M, Hagemeyer CE, Eisenhardt SU, Ahrens I, Bode C, Jackson SP, Peter K.
Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):e9-15.
http://www.ncbi.nlm.nih.gov/pubmed/17170374

Tiefe Beinvenenthrombosen. Diagnose und Therapie (CME Artikel)
Ahrens I, Bode C.
Internistische Praxis 47, 59-71 (2007)
http://bibnet.org/vufind/Record/ccmed951901852

Therapeutic inhibitors of platelet aggregation - from aspirin to integrin blockers.
Ahrens I, Schwarz M, Peter K, Bode C.
Transfusion Medicine and Hemotherapy 2007;34 (1): 44-54
http://dx.doi.org/DOI:10.1159/000097664